A phase 1/2 safety and efficacy study of TAK‐754 gene therapy: The challenge of achieving durable factor VIII expression in haemophilia A clinical trials
Haemophilia · 2025-01 · 31 (1) · 108-117
DOI: 10.1111/hae.15121 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Haemophilia, online erschienen am 23.12.2024. Verfasst von John Chapin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Rare Genetics and Hematology Therapeutic Area Unit, Takeda Development Center of the Americas, Cambridge, USA. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII, Genetic Therapy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda Pharmaceuticals International.
Abstract (Originalsprache)
Introduction
Haemophilia A is an X‐linked bleeding disorder resulting from a deficiency of factor VIII (FVIII). To date, multiple gene therapies have entered clinical trials with the goal of providing durable haemostatic protection from a single dose. TAK 754 (BAX 888) is an investigational AAV8‐based gene therapy containing a FVIII transgene. Reduction in CpG motifs was performed to reduce immunogenicity based on prior observations. Here, we describe the results of the first two cohorts treated with TAK 754.
Aim
To report clinical and translational results of the TAK‐754 phase 1/2 AAV gene therapy study for the treatment of haemophilia A.
Methods
A phase 1/2 single arm open‐label dose escalation study of TAK‐754 was performed in participants with severe haemophilia A (NCT03370172). Participants were monitored for safety events, endogenous FVIII activity and bleeding rates. Glucocorticoids were implemented to preserve transgene expression. A transcriptomics analysis was performed to evaluate immunogenicity along with additional post‐hoc analyses.
Results
Four participants were dosed in two cohorts. Infusion of TAK 754 was well‐tolerated. All participants developed mild transient transaminase elevation and subsequent loss of FVIII expression within the first 12 months of treatment despite use of glucocorticoids. Transcriptomic analysis did not demonstrate significant changes in immunogenicity signals in peripheral blood. One serious adverse event of hypophosphatemia occurred in the second cohort without obvious risk factors.
Conclusions
Sustained FVIII expression remains a challenge in haemophilia A AAV gene therapy trials. Mechanisms of transgene expression loss require further study as clinical studies enter long term follow‐up periods.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rare Genetics and Hematology Therapeutic Area Unit, Takeda Development Center of the Americas, Cambridge, USA.
- Hospital Universitario La Paz, Universidad Autónoma de Madrid, Madrid, Spain.
- Clinical Sciences, Rare Disease Therapeutic Area Unit, Takeda Development Center of the Americas, Cambridge, USA.
- Human Genetics, Preclinical and Translational Sciences, Takeda Development Center of the Americas, Cambridge, USA.
- Hematology Pathway Head, Rare Genetics and Hematology Drug Discovery Unit, Takeda Development Center of the Americas, Cambridge, USA.
- Unidad de Hemostasia y Trombosis, Hospital Universitario Regional de Málaga, Malaga, Spain.
ORCID-Profile: John Chapin, Maria Teresa Álvarez Román
Förderung
- Takeda Pharmaceuticals International
Zitieren
APA
Chapin, J., Álvarez Román, M. T., Ayash-Rashkovsky, M., Diogo, D., Kenniston, J., Lopez-Jaime, F. J., Maggiore, C., Mingot-Castellano, M. E., Rajavel, K., Rauch, A., Susen, S., von Grotthuss, M., Wagoner, M., & Wang, Q. (2025). A phase 1/2 safety and efficacy study of TAK‐754 gene therapy: The challenge of achieving durable factor VIII expression in haemophilia A clinical trials. Haemophilia, 31(1), 108-117. https://doi.org/10.1111/hae.15121
Vancouver
Chapin J, Álvarez Román MT, Ayash-Rashkovsky M, Diogo D, Kenniston J, Lopez-Jaime FJ, et al. A phase 1/2 safety and efficacy study of TAK‐754 gene therapy: The challenge of achieving durable factor VIII expression in haemophilia A clinical trials. Haemophilia. 2025;31(1):108-117. doi:10.1111/hae.15121
BibTeX
@article{Chapin2025,
author = {Chapin, John and Álvarez Román, Maria Teresa and Ayash-Rashkovsky, Mila and Diogo, Dorothee and Kenniston, Jon and Lopez-Jaime, Francisco-Jose and Maggiore, Caterina and Mingot-Castellano, María-Eva and Rajavel, Kavitha and Rauch, Antoine and Susen, Sophie and von Grotthuss, Marcin and Wagoner, Matt and Wang, Qin},
title = {A phase 1/2 safety and efficacy study of TAK‐754 gene therapy: The challenge of achieving durable factor VIII expression in haemophilia A clinical trials},
journal = {Haemophilia},
year = {2025},
volume = {31},
number = {1},
pages = {108--117},
doi = {10.1111/hae.15121}
}
EUVIMED